MedTrace Logo

Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer

NCT04803851 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2023-06-22

No results posted yet for this study

Summary

This study was designed to explore the clinical efficacy of Anlotinib combined with Anti-PD-1 antibody AK105 in the treatment of third- and above -line advanced pancreatic cancer patients, in order to find a better therapy strategy for pancreatic cancer patients.

Conditions

  • Anlotinib
  • Anti-PD-1 Antibody
  • Advanced Pancreatic Cancer

Interventions

DRUG

Anlotinib plus AK105

Anlotinib： a multi-kinase inhibitor AK105： an anti-PD-1 antibody

Sponsors & Collaborators

  • Peking Union Medical College Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-12
Primary Completion
2024-02-28
Completion
2024-06-29

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04803851 on ClinicalTrials.gov